MAPP BIOPHARMACEUTICAL, INC.

San Diego, CA · Biotech · Private

Monoclonal antibody therapeutic with extended half-life for Marburg Virus Disease protection

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · mappbio.com

Sector: Biotech
Headquarters: San Diego, CA
Total capital: $600M

Federal grants: $14.8M; 20 awards · 2014–2025; Rank in peer group#21 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $586M; 19 awards · Defense, Health and Human S; Rank in Biotech#1 of 4373
Granted patents: 2; 12 pending · first 2023; Rank in peer group#142 of 514

Capital timeline

Latest events

Feb 2026Federal contractDefense · Procurement Of Human Derived Monoclonal Antibodies And Antigens$21K
Sep 2025Federal contractDefense · Human-derived Monoclonal Antibodies And Recombinant Antigens$61K
Jun 2025Federal grantHealth and Human S · Phase II · A Novel Cost-Effective Multispecific Therapeutic for Dengue$295K
Jun 2025Federal contractDefense · Antibody & Antigen Supply$111K
Mar 2024Federal contractHealth and Human S · Development Of Medical Countermeasures Through Planned Clinical Trials And Outbreak Preparedness$5.6M
Sep 2022Federal contractHealth and Human S · Procurement Of Therapeutics For Ebola, Sudan And Marburg Viruses$221M
Sep 2022Federal contractHealth and Human S · This Cost-plus-fixed-fee Contract With Mapp Biopharmaceutical, Inc. (mapp Or Contractor) Is For The Development Of Mapp?s Therapeutic Intervention MBP091, As An Immunotherapy For The Treatment Of Marburg Virus Infection.$111M

Show 32 earlier federal awards

Jun 2022Federal grantHealth and Human S · Phase II · Development of highly potent human monoclonal for RSV immuno-prophylaxis$948K
Sep 2021Federal contractDefense · Base Year For Macv Contract Generates Macv IGG2$601K
Jul 2021Federal grantHealth and Human S · Phase II · Development of highly potent human monoclonal for RSV immuno-prophylaxis$801K
Sep 2020Federal contractHealth and Human S · Development Of A Pan-botulinum Neurotoxin Medical Countermeasure$16.4M
Jul 2020Federal grantDefense · Phase II · Marburg Virus Prophylactic Medical Countermeasure$999K
Jul 2020Federal contractDefense · STTR Phase II$1.5M
Jul 2020Federal grantHealth and Human S · Phase II · Development of highly potent human monoclonal for RSV immuno-prophylaxis$2.7M
Dec 2018Federal grantHealth and Human S · Phase I · Development of highly potent human monoclonals for RSV immunoprophylaxis$300K
Sep 2018Federal grantDefense · Phase I · Marburg Virus Prophylactic Medical Countermeasure$150K
Sep 2018Federal contractHealth and Human S · Igf::ot::igf$56.7M
Jun 2018Federal grantHealth and Human S · Phase II · Post-exposure immunotherapy for ricin exposure$298K
Jan 2018Federal grantHealth and Human S · Phase I · Development of highly potent human monoclonals for RSV immunoprophylaxis$600K
Sep 2017Federal contractHealth and Human S · Igf::ot::igf$65.8M
Sep 2017Federal contractHealth and Human S · Igf::ot::igf$7.5M
Aug 2017Federal grantHealth and Human S · Phase I · Direct Sequencing of Antibodies of the Influenza Immune Response$225K
Jul 2017Federal grantHealth and Human S · Phase II · MR191_An Immunoprotectantfor Marburg Virus$3M
Jan 2017Federal grantHealth and Human S · Phase I · Direct sequencing of serum antibodies after infection$255K
Aug 2016Federal grantHealth and Human S · Phase I · Rapid Response Agents Against Filovirus Outbreaks Using Vectored Immunoprophylaxis$240K
Jul 2016Federal grantHealth and Human S · Phase II · An SEB Immunoprotectant$307K
Jun 2016Federal contractHealth and Human S · Mapp Eap - Igf::cl::igf For Other Functionsexpanded Access Protocol For Zmapp$28.9M
Jun 2016Federal grantHealth and Human S · Phase II · An Immunoprotectant for Marburg Virus$1.0M
May 2016Federal contractDefense · Igf::ot::igf SBIR Phase II - Monthly Status Reports$1.0M
Jul 2015Federal grantHealth and Human S · Phase II · An SEB Immunoprotectant$1M
Jun 2015Federal grantHealth and Human S · Phase II · An Immunoprotectant for Marburg Virus$1.0M
Jun 2015Federal grantHealth and Human S · Phase I · A human monoclonal for RSV prophylaxis$300K
Jan 2015Federal grantHealth and Human S · Phase I · Pseudomonas antibodies with designed glycans$229K
Dec 2014Federal grantDefense · Phase I · Ricin Toxin Protective Monoclonal Antibodies with Improved Serum Half-Life$150K
Sep 2014Federal contractHealth and Human S · Igf::cl::igf For Other Functions Advanced Development Of Zmapp, An Ebola Virus Candidate Medical Countermeasure$52.4M
Jun 2014Federal contractDefense · SBIR Phase I$150K
Jun 2014Federal contractDefense · Igf::ot::igf Base Period - Psc: AN12 Research And Development Services$6.2M
Feb 2013Federal contractDefense · Base Year$11.2M
Jun 2012Federal contractDefense · Igg Fractionation Of Nhp Serum$70K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#21 · top 4%
Granted patents#142 · top 28%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 2 granted of 14

May 19, 2026GrantedAnti-respiratory Syncytial Virus Antibodies, Methods Of Their Generation And UseUSPTOUS 12,630,611
Jun 26, 2025PendingAntibodies Against HenipavirusesUSPTOApplication 18991145
Aug 15, 2023GrantedAnti-respiratory Syncytial Virus Antibodies, Methods Of Their Generation And UseUSPTOUS 11,725,045

Show all 14 patent records

Anti-respiratory Syncytial Virus Antibodies, Methods Of Their Generation And UseMay 19, 2026 · US 12,630,611Granted
Antibodies Against HenipavirusesJun 26, 2025 · Application 18991145Pending
Anti-respiratory Syncytial Virus Antibodies, Methods Of Their Generation And UseAug 15, 2023 · US 11,725,045Granted
Monoclonal Antibody Cocktails For Treatment Of Ebola InfectionsAug 29, 2019 · Application 16389646Pending
Monoclonal Antibody Cocktails For Treatment Of Ebola InfectionsAug 15, 2019 · Application 16370801Pending
Broadly Protective Antibody Cocktails For Treatment Of Filovirus Hemorrhagic FeverApplication PCTUS2017021842Pending
Broadly Protective Antibody Cocktails For Treatment Of Filovirus Hemorrhagic FeverApplication 62368688Pending
Monoclonal Antibody Cocktails For Treatment Of Ebola InfectionsApplication PCTUS2016031242Pending
Antibodies Against HenipavirusesApplication PCTUS2024061561Pending
Broadly Protective Antibody Cocktails for Treatment of Filovirus Hemorrhagic FeverApplication 62307118Pending
Antibodies Against OrthohantavirusesApplication PCTUS2024019994Pending
Antibodies Against HenipavirusesApplication 63614371Pending
mRNA-encoded Antibodies to Neutralize Sperm for Contraceptive PurposesApplication 62926771Pending
Monoclonal Antibody Cocktail For Treatment Of Ebola InfectionsApplication PCTUS2017030498Pending

INTEGRATED LABORATORY SYSTEMS, LLCSimilar federal contract value in Biotech · $271M in contracts
VENATORX PHARMACEUTICALS INCSimilar federal contract value in Biotech · $270M in contracts
AchaogenSimilar federal contract value in Biotech · $214M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.